University of Palermo, Department of Surgical, Oncological and Stomatological Sciences, Section of Medical Oncology , Via del Vespro 129 - 90127 Palermo , Italy +39 091 6552500 ; +39 091 6554529 ;
Expert Opin Biol Ther. 2014 Jan;14(1):103-14. doi: 10.1517/14712598.2014.859671.
Treatment of ovarian cancer has been long standardized with the inclusion of surgery and chemotherapy based on platinum and taxanes, this strategy reaching high remission rates. However, when this treatment fails, further options are available with little benefit. Since ovarian cancer has specific immunologic features, actually immunotherapy is under evaluation to overcome treatment failure in patients experiencing recurrence.
Immunogenicity of ovarian cancer and its relationship with clinical outcomes is briefly reviewed. The kinds of immunotherapeutic strategies are summarized. The clinical trials investigating immunotherapy in recurrent ovarian cancer patients are reported.
The results of these clinical trials about immunotherapy are interesting, but little clinical benefit has been achieved until now. For this reason, we could conclude that immunotherapy is quite different from other treatment options and it could change the global approach for recurrent ovarian cancer treatment. However, to date only fragmentary findings are available to define the real role of immunotherapy in this setting.
卵巢癌的治疗方法长期以来一直以手术和化疗为标准，化疗药物基于铂类和紫杉烷类，这种策略达到了很高的缓解率。然而，当这种治疗失败时，进一步的选择方案可用，但获益甚微。由于卵巢癌具有特定的免疫特征，实际上免疫疗法正在评估中，以克服复发患者的治疗失败。
简要回顾了卵巢癌的免疫原性及其与临床结局的关系。总结了各种免疫治疗策略。报告了在复发性卵巢癌患者中进行免疫治疗的临床试验结果。
这些关于免疫疗法的临床试验结果很有趣，但到目前为止，几乎没有取得临床获益。因此，我们可以得出结论，免疫疗法与其他治疗方法有很大的不同，它可能改变复发性卵巢癌治疗的整体方法。然而，迄今为止，只有零星的发现可以确定免疫疗法在这种情况下的真正作用。
